ArticleCurrent treatment options in neurology2012
Treatment of behavioral and psychological symptoms of Alzheimer's disease.
Article in Current treatment options in neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 66 citations in OpenAlex.
- Trial
- Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: a cluster randomized trial.European journal of pain (London, England) · 2014Trial
- Improving Well-being and Health for People with Dementia (WHELD): study protocol for a randomised controlled trial.Trials · 2014Trial
- Delirium Prevention and Management in Older Adults in the Emergency Department.Emergency medicine clinics of North America · 2025Review
- Neuroprotective Effect ofBiology · 2024Article
- Clusterization of Behavioral and Psychological Symptoms of Dementia as Assessed by Neuropsychiatric Inventory: A Case Against the Use of Principal Component Analysis.Journal of Alzheimer's disease : JAD · 2024Article
- Anticholinergic effect of resveratrol with vitamin E on scopolamine-induced Alzheimer's disease in rats: Mechanistic approach to prevent inflammation.Frontiers in pharmacology · 2023Article
- Psychotropic drug use among older people with major neurocognitive disorder: a cross-sectional study based on Swedish national registries.European journal of clinical pharmacology · 2022Article
- More than Just a Brain Disorder: A Five-Point Manifesto for Psychological Care for People with Huntington's Disease.Journal of personalized medicine · 2022Article
- Cannabinoids for behavioral symptoms in severe dementia: Safety and feasibility in a long-term pilot observational study in nineteen patients.Frontiers in aging neuroscience · 2022Article
- A Scientometrics Analysis and Visualization of Depressive Disorder.Current neuropharmacology · 2021Article
- Psychosis in Alzheimer's Disease.Current neurology and neuroscience reports · 2020Review
- New antipsychotic drugs for the treatment of agitation and psychosis in Alzheimer's disease: focus on brexpiprazole and pimavanserin.F1000Research · 2020Review
- Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease.Translational psychiatry · 2019Article
- Atypical presentation of progressive young onset dementia.BMJ case reports · 2018Article
- Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.Current neuropharmacology · 2016Review
- Treatment and Management of Dementia Due to Alzheimer's Disease.Current treatment options in neurology · 2015Article
- DISC1 regulates trafficking and processing of APP and Aβ generation.Molecular psychiatry · 2015Article
- Are the safety profiles of antipsychotic drugs used in dementia the same? An updated review of observational studies.Drug safety · 2014Review
- Dementia: Pain management in dementia--the value of proxy measures.Nature reviews. Neurology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
opinion statementBehavioral and psychological symptoms of dementia (BPSD) are frequent amongst people with Alzheimer's disease (AD) and other dementias, commonly confer risk to that person and others, and present a significant management challenge for clinicians. There is increasing evidence to support the value of simple psychological interventions and the treatment of pain as a first-line management strategy prior to pharmacotherapy. The most widely prescribed pharmacological treatments-atypical antipsychotics-have a modest but significant beneficial effect in the short-term treatment of aggression (over 6-12 weeks) but limited benefits in longer-term therapy. In addition, there have been increasing concerns regarding the potential for serious adverse outcomes, including stroke and death. The potential pharmacologic alternatives to atypical antipsychotics with the most encouraging preliminary evidence include memantine, carbamazepine, citalopram, and prazosin. Large, prospective, randomized placebo-controlled trials are needed to establish the role of these agents as clinical therapies for the treatment of BPSD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.